Ibrutinib Suppresses Intracellular Mycobacterium Tuberculosis Growth by Inducing Macrophage Autophagy

Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis (Mtb) infection. According to the latest Global Tuberculosis Report from World Health Organization (WHO) in 2018, there were more than 10 million new cases and 1.57 million deaths of TB in 2017.1 What's more, an estimated 2 billion people have latent TB infection (LTBI) and are at risk of re-activation of the disease.2,3 Although anti-TB treatment regimen is effective on drug-sensitive TB, problems with drug toxicity and increasing multidrug resistance (MDR) urge the discovery of new drugs and therapeutic strategies.

Source: Journal of Infection - March 10, 2020 Category: Infectious Diseases Authors: Yunlong Hu, Zhihua Wen, Song Liu, Yi Cai, Jiubiao Guo, Yuzhong Xu, Dachuan Lin, Jialou Zhu, Dechang Li, Xinchun Chen Source Type: research